Sign Out
Bortezomib is a substrate for cytochrome P450 3A4, 2C19, and 1A2. Patients who are concomitantly receiving Bortezomib and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy (see Pharmacology: Pharmacokinetics under Actions).
Patients on oral antidiabetic agents receiving Bortezomib treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.
Patients should be cautioned about the use of concomitant medications that may be associated with peripheral neuropathy (such as amiodarone, anti-virals, isoniazid, nitrofurantoin, or statins), or with a decrease in blood pressure.
Drug Laboratory Test Interaction: None known.
Lanjutkan dengan Google